3:09 PM Abstract No. 118 Cost impact of new technologies in interventional oncology and interventional radiology

To define the cost impact of several novel technologies in interventional oncology and interventional radiology using simplified cost effectiveness models. The impact of newly introduced technologies upon a population are often unknown until after broad community adoption. We sought to better understand the potential cost impact of several novel IR technologies in terms of the impact across a population, using simplified models (with multiple generalizations and assumptions). Comparisons were made for selected new technology vs. the standard technology in terms of impact on direct costs, with less emphasis on departmental overhead (administrative) and allocated (hospital) overhead. The assumption was made of total adoption versus zero adoption for example technologies: 1.Ultrasound Fusion for biopsy instead of CT 2.Angle-Nav MEMS tracker needle clip for biopsy instead of CT 3. Artificial intelligence-based image registration instead of electromagnetic tracking-based fusion interventions and 4. The addition of ThermoDox drug to thermal ablation of small solitary liver tumors, using phase 3 overall survival data. New technologies can have unforeseen cost implications upon adoption. Simplified “all or nothing“ adoption models can clarify the impact upon direct costs prior to adoption, to better inform the value and impact of the novel technologies before it is a “fait accompli.” Although speculative, some new IR technologies could be very cost-effective in specific clinically constrained scenarios: 1. Ultrasound Fusion for biopsy costs less than CT-guided biopsy 2.Angle-Nav MEMS tracker needle clip for biopsy costs less than CT 3. Artificial intelligence-based image registration costs less than electromagnetic tracking-based fusion interventions and 4. the addition of ThermoDox drug to thermal ablation of small solitary liver tumors could broaden indications for RFA and possibly augment QALY’s for patients with solitary 3-7 cm HCC, using Phase 3 survival data. Simulated cost analysis of new technologies can define specific methods of use that may have direct cost saving impact, and likewise also specific methods of use where the technology might add cost, without proven value.